back to Directory

Exscientia

Exscientia logo

Founded
2012
Patents
11
Clinical Trials
2
Publications
60

Technologies

AI Companies (Drug Discovery) Antibody Discovery Companies Pharmaceutical and Drug Discovery

At the forefront of small molecule drug discovery

We are the first company to automate drug design, surpassing conventional human endeavour.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

bispecific drugs polypharmacology drug design


Posts Mentioning This Company

13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)

  
According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies.  Some companies are incorporating AI tools …

11 Biopharma Trends to Watch in 2024

  
2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

  
Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

  
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies …

Insilico Medicine and Other AI Drug Discovery Companies Leading the Race

  
A Hong Kong-based artificial intelligence (AI)-driven drug discovery company Insilico Medicine has just announced the appointment of Dr. Michelle Chen as a Chief Business Officer (CBO) to oversee the company’s corporate strategies and business development activities. Dr. Chen is a lofty hire, having more than 20 years of experience in …

A Parade of AI-driven Biotechs Going Public in 2020-2021

  
Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …

Pharmaceutical AI in 2021: Key Developments So Far

  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …

Major VC Rounds For AI-driven Biotechs in 2020

  
The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year.  However, there is still a lot going on in drug discovery and …

Artificial Intelligence Yields Early Results in Drug Discovery

  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …

Pharmaceutical Giants Are Chasing R&D Deals With Smaller AI Startups

  
The first month of 2019 is not over yet, but there are already four major announcements about new research projects between large drug discovery corporations and smaller artificial intelligence (AI) companies -- this is more than the number of all similar announcements in the year 2014 combined -- only three.